Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...
VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of ...
Emerging discoveries in liquid biomarker research promise to transform the early detection, diagnosis and treatment ...
Morgan Stanley’s pivot is from “chip winners” to hyperscalers with AI infrastructure optionality. MSFT has the strongest mix ...
Investor's Business Daily on MSN
Why this biotech, up 14% since its breakout, is on the rise once again
Pharvaris stock jumped early Monday after the FDA agreed to review the company's experimental treatment for a serious ...
Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with ...
Asianet Newsable on MSN
Morgan Stanley warns chip stocks momentum is fading, favors three hyperscalers — JPMorgan says AI ‘unlikely’ to be only trade in town
According to a Bloomberg report citing a Morgan Stanley note, the firm picked Microsoft, Amazon, and Meta as its favorites ...
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...
Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...
The future food industry in the Netherlands is calling on the government to make at least €200M available via the EU's IPCEI mechanism to scale up alternative proteins.
3d
VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results